| 前收市價 | 135.35 |
| 開市 | 135.35 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 135.35 - 135.35 |
| 52 週波幅 | 118.16 - 152.06 |
| 成交量 | |
| 平均成交量 | 3,054 |
| 市值 | 215.718B |
| Beta 值 (5 年，每月) | 0.19 |
| 市盈率 (最近 12 個月) | 35.62 |
| 每股盈利 (最近 12 個月) | 3.80 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 2.86 (2.11%) |
| 除息日 | 2024年2月22日 |
| 1 年預測目標價 | 無 |
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
BenzingaAstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
Thursday, AstraZeneca Plc (NASDAQ:AZN) reported first-quarter sales of $12.68 billion, up 17% year over year (+19% at constant currency), slightly below the consensus of $11.83 billion. This was fueled by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines. The company’s adjusted EPADS reached $1.03, missing the consensus of $1.22. Also Read: AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO’s Pay Package Boost. R&D expenses rose a
Investor's Business DailyAstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
AstraZeneca stock bolted higher Thursday — and is now within striking distance of a breakout — after its cancer drugs propelled a sales beat.
